Viatris has faced volatility since its 2020 formation but is now in Phase 2 of its transformation. Learn why VTRS stock could ...

The Finance Minister is expected to prioritise economic growth, domestic manufacturing, and offer relief to consumers in the upcoming budget to address inflation, fiscal consolidation, and job creatio ...

Syngene reported 18% YoY growth in Q3FY25 net profit. Revenue rose 11% YoY. EBITDA margin improved to 31.4%. Company expects ...

Biocon advanced 2.41% to Rs 397.20 after its board is scheduled to meet on Monday, 27 January 2025, to consider and approve the raising of funds on a private placement basis.

Biocon stock price is poised for a fresh breakout from its consolidation range of 320-395, following nearly three and a half ...

Reuters Nifty continues to climb a wall of worry as it looks to be in the final leg of its rally before heading for a ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Here's a list of buy/sell recommendations for today from three analysts: Ankush Bajaj, Raja Venkatraman, and MarketSmith ...

The Nity50 opened with a significant gap up of 102 points at 23,306.20. However, sellers intervened and pulled the index down ...

As the US remains the top market for the Indian pharmaceutical industry, experts in India are now expecting opportunities for ...

China's rural healthcare gap impacts timely medical response; the EU plans to ban 'forever chemicals'; North America eases ...

India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major ...